James Posada, chief executive of Resolve, said: "We are very pleased to close this initial $2m of our series A financing and expect to complete the round with a third, corporate investor in the near future."
Resolve Therapeutics, a US-based healthcare provider, has raised $2m in the initial close of its series A round before bring in a corporate venturing unit later.
Venture firms New Science Ventures and Easton Capital provided the initial money. James Posada, chief executive of Resolve, said: "We are very pleased to close this initial $2m of our series A financing and expect to complete the round with a third, corporate investor in the near future."
[Editor’s note: no subsequent
